Protagonist Therapeutics, Inc. (PTGX)
144.85
+0.51
(+0.35%)
USD |
NASDAQ |
Oct 30, 16:00
144.96
+0.11
(+0.08%)
After-Hours: 20:00
Protagonist Therapeutics Stock Buybacks (Quarterly) : -9.743M for June 30, 2026
Stock Buybacks (Quarterly) Chart
Historical Stock Buybacks (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -9.743M |
| March 31, 2026 | -23.37M |
| December 31, 2025 | -2.837M |
| September 30, 2025 | -5.659M |
| June 30, 2025 | -2.925M |
| March 31, 2025 | -11.92M |
| December 31, 2024 | -4.031M |
| September 30, 2024 | -12.05M |
| June 30, 2024 | -2.572M |
| March 31, 2024 | -7.799M |
| December 31, 2023 | -0.527M |
| September 30, 2023 | -35.32M |
| June 30, 2023 | -108.84M |
| March 31, 2023 | -26.56M |
| December 31, 2022 | -0.553M |
| September 30, 2022 | -0.682M |
| June 30, 2022 | -0.68M |
| March 31, 2022 | -17.11M |
| December 31, 2021 | -2.173M |
| September 30, 2021 | -1.381M |
| June 30, 2021 | -125.39M |
| March 31, 2021 | -1.168M |
| Date | Value |
|---|---|
| December 31, 2020 | -126.98M |
| September 30, 2020 | -7.669M |
| June 30, 2020 | -123.11M |
| March 31, 2020 | -0.406M |
| December 31, 2019 | -0.014M |
| September 30, 2019 | -25.24M |
| June 30, 2019 | -10.63M |
| March 31, 2019 | -0.39M |
| December 31, 2018 | -0.479M |
| September 30, 2018 | -23.03M |
| June 30, 2018 | -0.074M |
| March 31, 2018 | -0.53M |
| December 31, 2017 | -64.76M |
| September 30, 2017 | -0.328M |
| June 30, 2017 | -0.087M |
| March 31, 2017 | -0.374M |
| December 31, 2016 | 0.852M |
| September 30, 2016 | -85.28M |
| June 30, 2016 | 0.75M |
| March 31, 2016 | -22.63M |
| March 31, 2015 | -0.002M |
Stock Buyback Definition
Stock buybacks are when companies buy back their own stock, removing it from the marketplace. Stock buybacks increase the value of the remaining shares because there is now less common stock outstanding and company earnings are split among fewer shares.
Stock Buybacks (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Stock Buybacks (Quarterly) Benchmarks
| Johnson & Johnson | 966.00M |
| AbbVie, Inc. | 9.00M |
| BioMarin Pharmaceutical, Inc. | -6.655M |
| Gilead Sciences, Inc. | 0.00 |
| Nektar Therapeutics | -364.57M |